Company Name: |
Shanghai Aladdin Bio-Chem Technology Co.,LTD
|
Tel: |
400-6206333 13167063860 |
Email: |
anhua.mao@aladdin-e.com |
Products Intro: |
Product Name:SKF 83566 hydrobromide CAS:108179-91-5 Purity:95% Package:10mg/RMB 1544.90;50mg/RMB 1980.00;5mg/RMB 926.90
|
1H-3-Benzazepin-7-ol,8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-,hydrobroMide(1:1) manufacturers
|
| 1H-3-Benzazepin-7-ol,8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-,hydrobroMide(1:1) Basic information |
Product Name: | 1H-3-Benzazepin-7-ol,8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-,hydrobroMide(1:1) | Synonyms: | 1H-3-Benzazepin-7-ol,8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-,hydrobroMide(1:1);SKF83566HG;8-bromo-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol:hydrobromide;1H-3-Benzazepin-7-ol,8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-,hydrobroMide(1;113762;8-Bromo-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol hydrobromide;CS-2574;SKF 83566 hydrobromide, D1 receptor antagonist (DMSO solution) | CAS: | 108179-91-5 | MF: | C17H19Br2NO | MW: | 413.15 | EINECS: | | Product Categories: | | Mol File: | 108179-91-5.mol |  |
| 1H-3-Benzazepin-7-ol,8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-,hydrobroMide(1:1) Chemical Properties |
storage temp. | Desiccate at RT | solubility | Soluble to 5 mM in water with gentle warming and to 100 mM in DMSO | form | Powder |
| 1H-3-Benzazepin-7-ol,8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-,hydrobroMide(1:1) Usage And Synthesis |
Uses | SKF 83566 Hydrobromide is a very potent and selective D1-like dopamine receptor antagonist, specifically at the 5-HT2 receptor. | in vivo | SKF 83566 hydrobromide (oral administration; 20 μg/mL; 7 days) alone has no effects on altering LTP (115%). However, combinnation of SKF 83566 and nicotine significantly blocks the enhancement of long-term synaptic potentiation (LTP) induced by pretreatment with nicotine (SKF 83566+nicotine+cocaine, 120%; nicotine+cocaine, 143%)[1]. Animal Model: | Male C57BL6/J mice (6- to 9-wk-old)[1] | Dosage: | 20 μg/mL (Together with nicotine for 7 d, followed by the injection of cocaine) | Administration: | Oral administration; 7 days | Result: | Blocked nicotine and cocaine-induced facilitation of LTP. |
| IC 50 | D1 Receptor; D5 Receptor; 5-HT2 Receptor: 11 nM (Ki) | storage | room temperature (desiccate) |
| 1H-3-Benzazepin-7-ol,8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-,hydrobroMide(1:1) Preparation Products And Raw materials |
|